Using fructokinase inhibitors to help treat alcohol use disorder
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
This study is exploring a new way to help people with alcohol use disorder by looking at a specific enzyme that influences cravings for sugar and alcohol, and it aims to create new medications that could reduce those cravings safely and effectively.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Colorado Research Partners, LLC NIH-funded |
| Lab location | 1 site (Centennial, United States) |
| Project ID | NIH-10659119 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating alcohol use disorder by targeting an enzyme called fructokinase, which plays a role in sugar and alcohol cravings. The study aims to develop a novel class of drugs that inhibit this enzyme, potentially reducing the desire for alcohol without the adverse effects associated with current treatments. By understanding how fructokinase affects alcohol preference, the research seeks to provide a safer and more effective treatment option for individuals struggling with alcohol dependence. Patients may be involved in trials to assess the efficacy and safety of these new medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are struggling with alcohol use disorder.
Not a fit: Patients who do not have alcohol use disorder or those who are not willing to participate in clinical trials may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, safer medication that effectively reduces cravings for alcohol in individuals with alcohol use disorder.
How similar studies have performed: While the approach of targeting fructokinase is novel, previous research has shown promise in using metabolic pathways to influence cravings and addiction behaviors.
Where this research is happening
Centennial, United States
- Colorado Research Partners, LLC — Centennial, United States (Active)
Researchers
- Principal investigator: Johnson, Richard Joseph — Colorado Research Partners, LLC
- Study coordinator: Johnson, Richard Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.